Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Acucela, Otsuka Enter Deals For Eye Drugs

This article was originally published in PharmAsia News

Executive Summary

Acucela's deal with Otsuka to develop two eye-disorder drugs follows news of the plan by Shionogi to buy out Sciele, pointing up the continued interest from Japanese pharma in U.S. firms

You may also be interested in...



Acucela Strikes Third Ophthalmology Deal With Otsuka For Glaucoma Drug

Seattle-based ophthalmology specialist Acucela has struck its third partnership with Japanese pharma Otsuka Pharmaceutical Co., this time to collaborate on development of a preclinical glaucoma treatment

Acucela Strikes Third Ophthalmology Deal With Otsuka For Glaucoma Drug

Seattle-based ophthalmology specialist Acucela has struck its third partnership with Japanese pharma Otsuka Pharmaceutical Co., this time to collaborate on development of a preclinical glaucoma treatment

Shionogi Gains U.S. Sales Force With $1.4 Billion Sciele Acquisition

TOKYO - Shionogi moved Sept. 1 to establish a sales presence in the U.S. through the acquisition of Atlanta-based Sciele Pharma. Boards of both firms approved the $1.42 billion purchase, for $31 per share, prior to the announcement

Related Content

UsernamePublicRestriction

Register

LL021506

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel